Malignant Neoplasm of Unknown Primary — Trials

Malignant Neoplasm of Unknown Primary — Trials · CancerIndex

Clinical trials

Registered studies

14,260 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4,163
Recruiting: 2,261
Ph III recruiting: 270
Growth YoY: +12.5%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,895)

clinicaltrialsPublishedShowing 1,951–1,971 of 1,971 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00056173	Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma	completed	Phase 1 / Phase 2	43	Aptose Biosciences Inc.INDUSTRY	1	Jan 7, 2008	clinicaltrials
NCT00165217	Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma	completed	Phase 2	37	Dana-Farber Cancer InstituteOTHER	1	Dec 21, 2007	clinicaltrials